Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VCYT
VCYT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VCYT News
Veracyte Reports 21% Revenue Growth in Q1 with Quadrupled EPS
2d ago
NASDAQ.COM
Veracyte Reports Strong Q1 Earnings, Shares Up 23%
2d ago
Fool
Veracyte Reports Strong Q4 2025 Earnings with 19% Revenue Growth
Feb 26 2026
seekingalpha
Veracyte Reports Q4 Earnings Exceeding Expectations
Feb 25 2026
seekingalpha
Veracyte to Participate in Investor Conferences
Feb 19 2026
Newsfilter
Veracyte to Release Q4 and Full-Year 2025 Financial Results
Feb 04 2026
Businesswire
Veracyte Inc Shares Enter Oversold Territory
Feb 04 2026
NASDAQ.COM
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
Jan 19 2026
NASDAQ.COM
Abbott Laboratories (ABT) Forecasts Q4 2025 Revenue of $11.79 Billion, Up 7.5%
Jan 19 2026
NASDAQ.COM
Veracyte Projects 10%-13% Revenue Growth for 2026
Jan 11 2026
Businesswire
Veracyte Reports $517M Full-Year Revenue, Up 16%
Jan 11 2026
Newsfilter
Oncolytics Biotech Achieves 33% Response Rate with Pelareorep in KRAS-Mutant Colorectal Cancer
Dec 31 2025
Newsfilter
Oncolytics Biotech Reports 33% Response Rate in KRAS-Mutant Colorectal Cancer with Pelareorep
Dec 31 2025
PRnewswire
Veracyte Raises 2025 Sales Guidance to $510 Million Amid Positive Market Trends
Dec 31 2025
Yahoo Finance
Veracyte Projects 14.1% Sales Growth to $508.6M in 2025
Dec 30 2025
NASDAQ.COM
Veracyte to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026
Dec 29 2025
Businesswire
Show More News
